Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Trial of Sacituzumab Govitecan-HZIY (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy

NCT07504588 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT07504588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07504588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Trial of Sacituzumab Govitecan-HZIY (SG) and Bevacizumab Versus Standard of Care Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Bevacizumab in Patients With Platinum-Sensitive Ovarian Cancer That Has Progressed on Prior Maintenance PARP Inhibitor Therapy
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Recruiting
Start date
September 24, 2026
Completion date
April 12, 2029
Enrollment
87 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent platinum-sensitive fallopian tube endometrioid adenocarcinoma, recurrent platinum-sensitive fallopian tube high grade serous adenocarcinoma, recurrent platinum-sensitive ovarian high grade endometrioid adenocarcinoma, recurrent platinum-sensitive ovarian high grade serous adenocarcinoma, recurrent platinum-sensitive primary peritoneal endometrioid adenocarcinoma, recurrent platinum-sensitive primary peritoneal high grade serous adenocarcinoma